Loading...
This year's GI Cancers Symposium was conducted virtually and in person January 20–22 in San Francisco. NEJM Journal Watch Oncology and Hematology Associate Editor David H. Ilson, MD, PhD, reports on a number of important and potentially practice-changing studies presented there. Abstracts can be viewed in the symposium's meeting library.
Researchers assessed the effect of early treatment discontinuation (ETD) in a pooled analysis of 11 trials in the ACCENT/IDEA database that evaluated 6 months of either adjuvant capecitabine/oxaliplatin or FOLFOX in patients with stage III colon cancer (abstract 11). ETD, defined as discontinuation of treatment before 75% of planned chemotherapy cyc…